Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2012

 

 

ALSERES PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   0-6533   87-0277826

(State or Other Jurisdiction

of Incorporation

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

239 South Street, Hopkinton, Massachusetts   01748
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (508) 497-2360

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Table of Contents

TABLE OF CONTENTS

 

Item 8.01. Other Information

  -3-

SIGNATURE

 

 

-2-

Table of Contents

Item 8.01. Other Information

On March 13, 2012 the Company received notice that Children’s Hospital Boston and Children’s Medical Center Corporation had filed a lawsuit in Middlesex Superior Court, Middlesex County, Massachusetts seeking to recover amounts alleged to be owed by the Company to the plaintiffs totaling $642,906. The Company does not agree that the amounts claimed are in fact owed and will pursue all legal remedies available to it to defend this claim.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Alseres Pharmaceuticals, Inc.
Date: March 19, 2012   By:  

/s/ Kenneth L. Rice, Jr.

    Kenneth L. Rice, Jr.
    Executive Vice President, Finance and Administration and Chief Financial Officer

 

-3-

Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Alseres Pharmaceuticals (CE) Charts.
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Alseres Pharmaceuticals (CE) Charts.